A Phase I Study of GFH312 in Healthy Chinese Subjects

Healthy Volunteer Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Study Evaluating the Pharmacokinetics and Safety of GFH312 in Healthy Chinese Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05991362
• Other study ID #: GFH312X1102
• Status: Completed
• Phase: Phase 1
• Start date: November 29, 2022
• Est. completion date: May 30, 2023

Study information

• Verified date: August 2023
• Source: Genfleet Therapeutics (Shanghai) Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study was to evaluate the pharmacokinetic profile and observe the safety of GFH312 after single and multiple administrations in healthy Chinese subjects.

Description:

This study was planned to enroll about 26 healthy subjects, subjects were planned to receive single administration of 100 mg GFH312, single administration of 200 mg GFH312, or multiple administrations of 120 mg GFH312, as well as their matching placebo. Subjects were randomized in 3:1 ratio in the single dose cohorts and in 4:1 ratio in the multiple dose cohort.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: May 30, 2023
• Est. primary completion date: February 13, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Voluntarily participate in the study and sign the informed consent;

• Male or female healthy subjects aged 18-55 years (inclusive) (single sex ratio not less than 25% of the sample size of each cohort);

• Body mass index (BMI) between 18-28 kg/m2 (inclusive), and weight = 50kg; BMI = Weight (kg) /[Height (m)]2.

• During the screening period and day 1, patients with normal or abnormal results but no clinical significance based on detailed medical history, comprehensive physical examination, laboratory examination (blood routine, blood biochemistry, urine routine, coagulation function), 12-lead electrocardiogram and vital signs.

• Able to communicate well with researchers, understand and comply with research requirements.

Exclusion Criteria:

• Any procedure or disease that may significantly alter drug absorption, distribution, metabolism, or excretion, or participation in this study may compromise the safety of the subject.

• Tuberculin test positive

• Abnormal electrocardiogram with clinical significance

• Use any prescription drugs, Chinese herbs and/or OTC or health products within 2 weeks before starting the administration.

• Women who are pregnant or breastfeeding, or subjects with positive pregnancy test results at the time of screening or at baseline, or who plan to become pregnant during the study period or within 30 days after the end of the study.

• Subjects who have any factors deemed unsuitable for participation in this study by the investigator.

Related Conditions & MeSH terms

• Healthy Volunteer

Intervention

Drug:
• GFH312 100 mg
Participants receive single dose of GFH312 100 mg orally
• GFH312 200 mg
Participants receive single dose of GFH312 200 mg orally
• GFH312 120mg
Participants receive daily dose of GFH312 120mg orally for fourteen consecutive days

Other:
• Placebo
Participants receive placebo matching with GFH312

Locations

Country	Name	City	State
China	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang Genfleet Therapeutics Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Observed Plasma Concentration (Cmax) of GFH312	The maximum observed plasma concentration (Cmax) was estimated based on the plasma concentrations of GFH312.	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4.
Primary	Time to peak drug concentration (Tmax) of GFH312	The time it takes for a drug to reach the maximum concentration (Cmax) after administration of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4.
Primary	Terminal Elimination Half Life (t1/2) of GFH312	The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4; for multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
Primary	Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of GFH312	The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) was estimated based on the plasma concentrations of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4.
Primary	Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of GFH312	The area under the plasma concentration-time curve from time zero to infinity (AUC 0-inf) was estimated based on the plasma concentrations of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4.
Primary	The apparent systemic (or total body) clearance from plasma (or serum or blood (CL/F) following extravascular administration of GFH312	The systemic clearance (CL) was estimated based on the plasma concentrations of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4; for multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
Primary	The apparent volume of distribution during the terminal elimination phase (Vd/F) following extravascular administration of GFH312	The volume of distribution was estimated based on the plasma concentrations of GFH312	For single dose groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 6, 8, 12 hours on day1; day2, day3, day4; for multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
Primary	The observed maximum plasma (or serum or blood) concentration following drug administration at steady state (Cmax,ss)	Observed maximum concentration in the dosing interval at steady state	For multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
Primary	The lowest plasma (or serum or blood) concentration observed during a dosing interval at steady state (Cmin,ss)	Observed minimum concentration in the dosing interval at steady state.	For multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
Primary	Time to reach maximum concentration in the dosing interval at steady state (Tmax,ss)	If the same Cmax concentration occurs at different time points, Tmax is assigned to the first occurrence of Cmax.	For multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
Primary	The area under the plasma (or serum or blood) concentration-time curve from time zero to the end of the dosing interval tau (AUCtau,ss)	Dose-normalized AUC0- t, calculated as AUC0-t divided by actual dose administered.	For multiple doses groups 30 minutes pre-dose, and at 0.5, 1, 2, 4, 8, 12 hours on day 1; day2, day7, day 13, day14, day15.
Secondary	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	An adverse event (AE) is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly or birth defect in the offspring of a participant who received the study drug.	up to 30 days after the last study drug administration